Rituximab therapy for HIV-associated Castleman disease

Marcelin, Anne–Geneviève; Aaron, Laurent; Mateus, Christine; Gyan, Emmanuel; Gorin, Isabelle; Viard, Jean‐Paul; Cálvez, Vincent; Dupin, Nicolas

doi:10.1182/blood-2003-03-0951

Cited by 136 publications

(95 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Targeting CD20 by Rituximab Rituximab is a monoclonal chimeric antibody that targets CD20 on B cells, leading to B-cell lymphodepletion via activating complement-dependent cytotoxicity and antibodydependent cell-mediated cytotoxicity [65]. Rituximab was first introduced as a treatment for HIV ϩ HHV-8 ϩ patients with MCD.…”

Section: Targeted Therapymentioning

confidence: 99%

Castleman's Disease: From Basic Mechanisms to Molecular Therapeutics

2011

View full text Add to dashboard Cite

Castleman's disease is a rare lymphoproliferative disorder in which there has been recent progress in elucidating underlying mechanisms with potential therapeutic implications. Unicentric Castleman's disease is an indolent condition that is often treated with local approaches. In contrast, patients with multicentric Castleman's disease (MCD) have a less favorable prognosis and require systemic treatment. Cytotoxic chemotherapy, with its attendant risk for toxicity, has been widely used to treat MCD, with variable efficacy. The discovery of putative etiologic factors and targets in MCD, particularly human herpes virus 8, CD20, and interleukin (IL)-6, has been translated into the use of rituximab and anti-IL-6-based therapy, as well as antiviral agents. In this article, we review the current state of the art of our understanding of Castleman's disease and its treatment and we provide insight into future treatment strategies based on disease biology. The Oncologist 2011;16:497-511

show abstract

Section: Targeted Therapymentioning

confidence: 99%

Castleman's Disease: From Basic Mechanisms to Molecular Therapeutics

2011

View full text Add to dashboard Cite

show abstract

“…7,13,14 Treatment options for iMCD patients who fail anti-IL-6 therapy are more limited and based on experience from small case series. Additional treatment options include radical lymph node resection, glucocorticoids, cytotoxic chemotherapy, immunomodulators, rituximab, 15 and anti-IL-1 therapy. 16 The lack of longitudinal clinical and immunophenotypic data for CD has made the diagnosis, treatment, and management of the disease challenging.…”

Section: Introductionmentioning

confidence: 99%

Clinical and pathological characteristics of HIV- and HHV-8–negative Castleman disease

Cortes³

et al. 2017

Blood

144

156

View full text Add to dashboard Cite

show abstract

“…Rituximab is an anti-CD20 mAb, commonly used for EBVpositive PTLD (16) and, as with the case presented here, this contributes to complete and prolonged remission of MCD (17,18). In MCD, HHV-8 infects plasmablasts located in the mantle zone, which variably express the CD20 surface antigen (19). This has provided the rationale for using rituximab, which has shown promising responses in two prospective trials in MCD in the HIV setting (20,21).…”

Section: Discussionmentioning

confidence: 99%

Successful Treatment of Iatrogenic Multicentric Castleman’s Disease Arising Due to Recrudescence of HHV-8 in a Liver Transplant Patient

Speicher

Sehu

Mollee

et al. 2014

American Journal of Transplantation

View full text Add to dashboard Cite

We describe the case of a 59‐year‐old HIV‐negative male who developed multicentric Castleman's disease (MCD) 1 year postliver transplantation due to recrudescence of a pretransplant human herpesvirus‐8 (HHV‐8) infection. He presented with fevers, dry cough, weight loss and drenching night sweats. Routine investigations were all unremarkable. Computerized axial tomography (CT) scans showed splenomegaly and intra‐abdominal lymphadenopathy, confirmed by positron emission tomography. Cervical lymph node biopsies were consistent with MCD. The presence of HHV‐8 was confirmed on immunohistochemistry. Peripheral blood HHV‐8 quantitative polymerase chain reaction (qPCR) monitoring showed a threefold decrease in viremia in the first week of treatment with ganciclovir but had little impact on clinical symptoms. Reducing immunosuppression and switching to rituximab resolved clinical symptoms and produced a negative HHV‐8 qPCR result. Retrospective molecular testing of sera collected pre‐ and immediately posttransplantation confirmed preexisting HHV‐8 in the host. This is the first reported case of an HIV‐negative postliver transplant patient developing MCD that manifested as posttransplant lymphoproliferative disorder due to recrudescence of HHV‐8. We propose (1) the introduction of the term iatrogenic Castleman's disease (CD) for this and similar cases, (2) rituximab should be considered as a treatment option for CD and (3) consideration be given to a change to the World Health Organization classification of CD to incorporate such cases.

show abstract

Rituximab therapy for HIV-associated Castleman disease

Cited by 136 publications

References 12 publications

Castleman's Disease: From Basic Mechanisms to Molecular Therapeutics

Castleman's Disease: From Basic Mechanisms to Molecular Therapeutics

Clinical and pathological characteristics of HIV- and HHV-8–negative Castleman disease

Successful Treatment of Iatrogenic Multicentric Castleman’s Disease Arising Due to Recrudescence of HHV-8 in a Liver Transplant Patient

Contact Info

Product

Resources

About